Bone turnover markers

Arjmandi et al., 1998a,b 95 d old OVX rats 35 d casein diet after OVX, then 65 d soy protein with isoflavones (9 mg/d) No significant effect of soy protein in reversal of bone loss, assessed by BMD. Soy induced femoral lGF-1 mRNA and some increases in bone turnover markers... 

Picherit et al., 2001 7 month old OVX adult rats 3 doses of isoflavone extract (20, 40, 80 mg/kg body wt/d) for 91 d Isoflavones reversed femoral failure load, total femoral, diphyseal or metaphyseal BMDs and normalized bone turnover markers induced by OVX. Optimal dose without uterotrophic effect was 40 mg/kg body wt... 

Clinical trials on postmenopausal women with osteoporosis have demonstrated that raloxifene reduces bone turnover markers by 25-35% after 1 year of treatment and reduces the relative risk of the occurrence of new vertebral fractures by 30-50% after 3 years of treatment (Ettinger et al. 1999). A post hoc analysis in women at high risk for cardiovascular diseases also showed a reduction of 40% in the rate of new cardiovascular events (Barrett-Connor et al. 2002), with no observed reduction in the overall study population after 4 years of treatment in the MORE trial. 

Doran PM, Riggs BL, Atkinson EJ, Khosla S (2001) Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 16 2118-2125... 

A 2-year randomized controlled study in 90 women compared the effects of oral tibolone doses of 1.25 mg/day and 2.5 mg/day on bone loss in the early postmenopausal period all took calcium 1000 mg/day. Vertebral and femoral bone density rose in both treated groups but fell in the control group, and bone turnover markers (urinary excretion of hydroxyproline/creatinine and plasma osteocalcin concentrations) were similarly affected favorably in the treated groups, as was the incidence of hot flushes/ flashes (5). Studies such as this still leave open the question of the advisability of continuing tibolone treatment over a longer period. While tibolone has indeed been shown to benefit mineral bone density, few data are available to show whether it lowers fracture incidence nor is it clear whether there is a link between tibolone and breast cancer (6). 

Postmenopause is associated with a global increase in bone turnover markers (Kushida et al, 1995 Vernejoul, 1998). These markers predict bone loss... 

FIG. 18 Effect of serum lycopene on protein oxidation and bone turnover markers in 33 postmenopausal volunteers. 

G10. Gordon, C. M., Grace, E., Jean-Emans, S., Goodman, E., Crawford, M. H., and Leboff, M. S., Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa J. Bone Miner Res. 14, 136-145 (1999). 

Bone mineral density, bone turnover markers, and adrenal glucocorticoid hormones have been measured in 53 patients (34 women, 19 men) with chronic bronchial asthma who took either inhaled beclomethasone or budesonide in doses of at least 1500 micrograms/day for at... 

Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996 81 3366-71. 

Delmas PD, Vrijens B, van de Langerijt L, Roux C, Eastell R, Ringe JD, et al. 2003. Effect of reinforcement with bone turnover marker results on persistence with risedronate treatment in postmenopausal... 

Kruk [49] Aminobisphosphonates LRP5 Men, Caucasian NO association with changes in BMD or bone turnover markers... 

Eastell, R., Hannon, R.A., Cuzick, J., Dowsett, M., Clack, G. and Adams, J.E. (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). Journal of Bone and Mineral Research, 21, 1215-1223. 

Vural, P., Akgul, C., and Canbaz, M. (2006) Effects of hormone replacement therapy on plasma pro inflammatory and anti inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmaceutical Research, 54, 298 302. 

Tsutsumi, H., K. Katagiri, M. Morimoto, T. Nasu, M. Tanigawa, and K. Mamba. 2004. Diurnal variation and age-related changes of bone turnover markers in female Gottingen minipigs. Laboratory Animals 38 439-446. 

Saadi, H. F., Nagelkerke, N., Benedict, S., et al. 2006. Predictors and relationships of serum 25 hydroxyvitamin D concentration with bone turnover markers, bone mineral density, and vitamin D receptor genotype in Emirati women. Bone, 39 113 3. 

Taku, K., Melby, M.K., Kurzer, M.S., Mizuno, S., Watanabe, S., and Ishimi, Y. 2010b, Effects of soy isoflavone supplements on bone turnover markers in menopausal women systematic review and meta-analysis of randomized eontrolled trials. Bone 47,413-423. 

Grimnes G, Joakrmsen R, Figenschau Y, Torjesen PA, Almas B, Jorde R. The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass-a randomized controUed 1-year trial. Osteoporos Int January 2012 23(1) 201-11. 

In a 52-week, double-blind, randomised study, 226 postmenopausal women with type 2 diabetes received therapy with rosiglitazone 4 mg daily. Rosiglitazone was associated with small reductions in bone mineral density in e femoral neck, total hip, and lumbar spine with increased bone turnover markers. [67 ... 

---